Mathew L Thakur

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8334252/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	SPECT Radiochemistry. , 2021, , 479-492.		О
2	Imaging urothelial bladder cancer: A VPAC PET targeted approach. Canadian Journal of Urology, 2021, 28, 10596-10602.	0.0	0
3	Targeting VPAC1 Receptors for Imaging Glioblastoma. Molecular Imaging and Biology, 2020, 22, 293-302.	1.3	4
4	Evaluating Ga-68 Peptide Conjugates for Targeting VPAC Receptors: Stability and Pharmacokinetics. Molecular Imaging and Biology, 2019, 21, 130-139.	1.3	11
5	Advanced approaches to imaging primary breast cancer: an update. Clinical and Translational Imaging, 2019, 7, 381-404.	1.1	Ο
6	In vivo investigation of the tissue response to commercial Teflon insulin infusion sets in large swine for 14 days: the effect of angle of insertion on tissue histology and insulin spread within the subcutaneous tissue. BMJ Open Diabetes Research and Care, 2019, 7, e000881.	1.2	12
7	Murine <i> <scp>MPDZ</scp> </i> â€linked hydrocephalus is caused by hyperpermeability of the choroid plexus. EMBO Molecular Medicine, 2019, 11, .	3.3	24
8	Currently Available Radiopharmaceuticals for Imaging Infection and the Holy Grail. Seminars in Nuclear Medicine, 2018, 48, 86-99.	2.5	33
9	VPAC1-targeted PET/CT scan: improved molecular imaging for the diagnosis of prostate cancer using a novel cell surface antigen. World Journal of Urology, 2018, 36, 719-726.	1.2	5
10	A glance at imaging bladder cancer. Clinical and Translational Imaging, 2018, 6, 257-269.	1.1	11
11	Development of a voided urine assay for detecting prostate cancer nonâ€invasively: a pilot study. BJU International, 2017, 119, 885-895.	1.3	6
12	VPAC1 Targeted 64 Cu-TP3805 kit preparation and its evaluation. Nuclear Medicine and Biology, 2017, 51, 55-61.	0.3	4
13	Evaluation of a PACAP Peptide Analogue Labeled with ⁶⁸ Ga Using Two Different Chelating Agents. Cancer Biotherapy and Radiopharmaceuticals, 2016, 31, 29-36.	0.7	5
14	VPAC1 Targeted 64Cu-TP3805 Positron Emission Tomography Imaging of Prostate Cancer: Preliminary Evaluation in Man. Urology, 2016, 88, 111-118.	0.5	21
15	Radiolabeled biomolecules for specific imaging of cancers of the breast, prostate and lungs. Journal of Radioanalytical and Nuclear Chemistry, 2014, 302, 857-867.	0.7	0
16	CCR5 Receptor Antagonists Block Metastasis to Bone of v-Src Oncogene–Transformed Metastatic Prostate Cancer Cell Lines. Cancer Research, 2014, 74, 7103-7114.	0.4	58
17	Fluorescence Detection of <i>KRAS2</i> mRNA Hybridization in Lung Cancer Cells with PNA-Peptides Containing an Internal Thiazole Orange. Bioconjugate Chemistry, 2014, 25, 1697-1708.	1.8	32
18	Determining efficacy of breast cancer therapy by PET imaging of HER2 mRNA. Nuclear Medicine and Biology, 2013, 40, 994-999.	0.3	11

#	Article	IF	CITATIONS
19	Effects of Hypoxanthine Substitution in Peptide Nucleic Acids Targeting <i>KRAS2</i> Oncogenic mRNA Molecules: Theory and Experiment. Journal of Physical Chemistry B, 2013, 117, 11584-11595.	1.2	25
20	VPAC1 Receptors for Imaging Breast Cancer: A Feasibility Study. Journal of Nuclear Medicine, 2013, 54, 1019-1025.	2.8	29
21	Molecular Determinants of Epidermal Growth Factor Binding: A Molecular Dynamics Study. PLoS ONE, 2013, 8, e54136.	1.1	61
22	Consistent Surgeon Evaluations of Three-Dimensional Rendering of PET/CT Scans of the Abdomen of a Patient with a Ductal Pancreatic Mass. PLoS ONE, 2013, 8, e75237.	1.1	1
23	Fluorescent Peptide–PNA Chimeras for Imaging Monoamine Oxidase A mRNA in Neuronal Cells. Bioconjugate Chemistry, 2012, 23, 158-163.	1.8	19
24	Receptor-Specific Peptides for Targeting of Liposomal, Polymeric, and Dendrimeric Nanoparticles in Cancer Diagnosis and Therapy. Current Molecular Imaging, 2012, 1, 3-11.	0.7	2
25	Targeting Apoptosis for Optical Imaging of Infection. Molecular Imaging and Biology, 2012, 14, 163-171.	1.3	19
26	PET imaging of EGFR expression in nude mice bearing MDA-MB-468, a human breast adenocarcinoma. Nuclear Medicine Communications, 2011, 32, 563-569.	0.5	13
27	Three dimensional projection environment for molecular design and surgical simulation. Studies in Health Technology and Informatics, 2011, 163, 691-5.	0.2	1
28	Imaging Spontaneous MMTVneu Transgenic Murine Mammary Tumors: Targeting Metabolic Activity Versus Genetic Products. Journal of Nuclear Medicine, 2010, 51, 106-111.	2.8	18
29	Physiologically Based Pharmacokinetics of Molecular Imaging Nanoparticles for mRNA Detection Determined in Tumor-Bearing Mice. Oligonucleotides, 2010, 20, 117-125.	2.7	23
30	Imaging Human Pancreatic Cancer Xenografts by Targeting Mutant <i>KRAS2</i> mRNA with [¹¹¹ In]DOTA _{<i>n</i>} -Poly(diamidopropanoyl) ^{<i>m</i>} - <i>KRAS2</i> PNA- <scp>d</scp> (Cys-Ser-Lys-Cys) Nanoparticles. Bioconjugate Chemistry, 2010, 21, 731-740.	1.8	30
31	Apoptotic abscess imaging with 99mTc-HYNIC-rh-Annexin-V. Nuclear Medicine and Biology, 2010, 37, 29-34.	0.3	8
32	Genetic and Molecular Approaches to Imaging Breast Cancer. , 2010, , 163-182.		1
33	Imaging oncogene expression. European Journal of Radiology, 2009, 70, 265-273.	1.2	15
34	John McAfee, MD (1926–2008), In Memoriam. Nuclear Medicine and Biology, 2009, 36, 343-344.	0.3	0
35	Recent Trends in Soft-Tissue Infection Imaging. Seminars in Nuclear Medicine, 2009, 39, 115-123.	2.5	60
36	Genomic Biomarkers for Molecular Imaging: Predicting the Future. Seminars in Nuclear Medicine, 2009, 39, 236-246.	2.5	23

#	Article	IF	CITATIONS
37	Design of (Gdâ€DO3A) _{<i>n</i>} â€polydiamidopropanoylâ€peptide nucleic acidâ€ <scp>D</scp> (Cys‣er‣ys ys) magnetic resonance contrast agents. Biopolymers, 2008, 89, 1	061-10 76 .	18
38	An Antimetastatic Role for Decorin in Breast Cancer. American Journal of Pathology, 2008, 173, 844-855.	1.9	136
39	Guanylyl Cyclase C–Induced Immunotherapeutic Responses Opposing Tumor Metastases Without Autoimmunity. Journal of the National Cancer Institute, 2008, 100, 950-961.	3.0	48
40	PET Imaging of VPAC1 Expression in Experimental and Spontaneous Prostate Cancer. Journal of Nuclear Medicine, 2008, 49, 112-121.	2.8	46
41	Radiohybridization PET imaging of KRAS G12D mRNA expression in human pancreas cancer xenografts with [64Cu]DO3A-peptide nucleic acid-peptide nanoparticles. Cancer Biology and Therapy, 2007, 6, 948-956.	1.5	42
42	Simulation of a pinhole-collimator insert for small animal PET using GATE. , 2007, , .		1
43	PET Imaging of CCND1 mRNA in Human MCF7 Estrogen Receptor Positive Breast Cancer Xenografts with Oncogene-Specific [64Cu]Chelator-Peptide Nucleic Acid-IGF1 Analog Radiohybridization Probes. Journal of Nuclear Medicine, 2007, 48, 1699-1707.	2.8	41
44	Receptor-mediated internalization of chelator–PNA–peptide hybridization probes for radioimaging or magnetic resonance imaging of oncogene mRNAs in tumours. Biochemical Society Transactions, 2007, 35, 72-76.	1.6	17
45	Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating peptide (PACAP) receptor specific peptide analogues for PET imaging of breast cancer: In vitro/in vivo evaluation. Regulatory Peptides, 2007, 144, 91-100.	1.9	37
46	VEGF Trap in Combination With Radiotherapy Improves Tumor Control in U87 Glioblastoma. International Journal of Radiation Oncology Biology Physics, 2007, 67, 1526-1537.	0.4	123
47	Report of a Summit on Molecular Imaging. American Journal of Roentgenology, 2006, 186, 297-299.	1.0	23
48	Endorepellin In Vivo: Targeting the Tumor Vasculature and Retarding Cancer Growth and Metabolism. Journal of the National Cancer Institute, 2006, 98, 1634-1646.	3.0	106
49	Decorin Protein Core Inhibits in Vivo Cancer Growth and Metabolism by Hindering Epidermal Growth Factor Receptor Function and Triggering Apoptosis via Caspase-3 Activation. Journal of Biological Chemistry, 2006, 281, 26408-26418.	1.6	157
50	Receptor-Specific Targeting with Complementary Peptide Nucleic Acids Conjugated to Peptide Analogs and Radionuclides. , 2006, , 61-88.		1
51	Imaging thromboembolism with fibrin-avid 99mTc-peptide: evaluation in swine. Journal of Nuclear Medicine, 2006, 47, 155-62.	2.8	27
52	Imaging cancer gene activity in patients from outside the body. Biotechnology Healthcare, 2006, 3, 45-8.	0.2	0
53	99mTc-Fanolesomab: affinity, pharmacokinetics and preliminary evaluation. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2006, 50, 104-12.	0.4	10
54	Radionuclide–Peptide Nucleic Acid in Diagnosis and Treatment of Pancreatic Cancer. , 2005, 106, 135-19.	2.	1

Radionuclide–Peptide Nucleic Acid in Diagnosis and Treatment of Pancreatic Cancer. , 2005, 106, 135-192. 54

4

#	Article	IF	CITATIONS
55	Chemistry of Gallium and Indium Radiopharmaceuticals. , 2005, , 363-399.		6
56	External Imaging ofCCND1,MYC, andKRASOncogene mRNAs with Tumor-Targeted Radionuclide-PNA-Peptide Chimeras. Annals of the New York Academy of Sciences, 2005, 1059, 106-144.	1.8	41
57	Receptor-specific targeting with complementary peptide nucleic acids conjugated to peptide analogs and radionuclides. International Journal of Peptide Research and Therapeutics, 2005, 10, 191-214.	0.9	Ο
58	Report of a Summit on Molecular Imaging. Radiology, 2005, 236, 753-755.	3.6	60
59	SYNTHESIS OF NOVEL PEPTIDE NUCLEIC ACID-PEPTIDE CHIMERA FOR NON-INVASIVE IMAGING OF CANCER. Nucleosides, Nucleotides and Nucleic Acids, 2005, 24, 409-414.	0.4	19
60	Radiolabeled Peptides in Oncology. BioDrugs, 2005, 19, 145-163.	2.2	87
61	Noninvasive Molecular Imaging of MYC mRNA Expression in Human Breast Cancer Xenografts with a [99mTc]Peptideâ^'Peptide Nucleic Acidâ^'Peptide Chimera. Bioconjugate Chemistry, 2005, 16, 70-79.	1.8	41
62	TUMOR-TARGETING PEPTIDE-PNA-PEPTIDE CHIMERAS FOR IMAGING OVEREXPRESSED ONCOGENE mRNAS. Nucleosides, Nucleotides and Nucleic Acids, 2005, 24, 1085-1091.	0.4	12
63	Sentinel Lymph Nodes in a Swine Model with Melanoma: Contrast-enhanced Lymphatic US. Radiology, 2004, 230, 727-734.	3.6	165
64	PET imaging of oncogene overexpression using 64Cu-vasoactive intestinal peptide (VIP) analog: comparison with 99mTc-VIP analog. Journal of Nuclear Medicine, 2004, 45, 1381-9.	2.8	49
65	External imaging of CCND1 cancer gene activity in experimental human breast cancer xenografts with 99mTc-peptide-peptide nucleic acid-peptide chimeras. Journal of Nuclear Medicine, 2004, 45, 2070-82.	2.8	43
66	Imaging Oncogene Expression. Annals of the New York Academy of Sciences, 2003, 1002, 165-188.	1.8	17
67	Receptor-specific targeting with complementary peptide nucleic acids conjugated to peptide analogs and radionuclides. International Journal of Peptide Research and Therapeutics, 2003, 10, 191-214.	0.1	Ο
68	Oncogene mRNA Imaging with99mTc-Chelator-PNA-Peptides ChemInform, 2003, 34, no.	0.1	0
69	Receptor-specific targeting with complementary peptide nucleic acids conjugated to peptide analogs and radionuclides. International Journal of Peptide Research and Therapeutics, 2003, 10, 191-214.	0.9	1
70	99mTc-peptide-peptide nucleic acid probes for imaging oncogene mRNAs in tumours. Nuclear Medicine Communications, 2003, 24, 857-863.	0.5	27
71	The Use of Radiolabeled Monoclonal Antibodies in Inflammatory Bowel Diseases. , 2003, , 40-46.		0
72	Role of lipid-soluble complexes in targeted tumor therapy. Journal of Nuclear Medicine, 2003, 44, 1293-300.	2.8	8

#	Article	IF	CITATIONS
73	Solid phase preparations of99mTc labeled radiopharmaceuticals. Journal of Labelled Compounds and Radiopharmaceuticals, 2002, 45, 231-239.	0.5	1
74	Radiolabeled peptides in the diagnosis and therapy of oncological diseases. Applied Radiation and Isotopes, 2002, 57, 749-763.	0.7	98
75	Oncogene mRNA imaging with 99mTc-chelator-PNA-peptides. Russian Chemical Bulletin, 2002, 51, 1083-1099.	0.4	2
76	Radiolabeled peptides in diagnosis and therapy. Seminars in Nuclear Medicine, 2001, 31, 296-311.	2.5	49
77	99mTc labeled VIP analog: evaluation for imaging colorectal cancer. Nuclear Medicine and Biology, 2001, 28, 445-450.	0.3	37
78	Imaging infection with LeuTech®. Nuclear Medicine Communications, 2001, 22, 513-519.	0.5	24
79	Fibrin avid ^{99m} TCâ€peptide for imaging thrombosis. Journal of Labelled Compounds and Radiopharmaceuticals, 2001, 44, S48.	0.5	2
80	A receptor-specific peptide for imaging infection and inflammation. Nuclear Medicine Communications, 2000, 21, 1063-1070.	0.5	18
81	Imaging Tumors in Humans with Tcâ€99mâ€VIP. Annals of the New York Academy of Sciences, 2000, 921, 37-44.	1.8	28
82	99mTc-labeled vasoactive intestinal peptide analog for rapid localization of tumors in humans. Journal of Nuclear Medicine, 2000, 41, 107-10.	2.8	51
83	Imaging vascular thrombosis with 99mTc-labeled fibrin alpha-chain peptide. Journal of Nuclear Medicine, 2000, 41, 161-8.	2.8	36
84	Neutrophil-specific 99mTc-labeled anti-CD15 monoclonal antibody imaging for diagnosis of equivocal appendicitis. Journal of Nuclear Medicine, 2000, 41, 449-55.	2.8	26
85	Labelling of platelets with indium-111 oxine and technetium-99m hexamethylpropylene amine oxime: suggested methods. European Journal of Nuclear Medicine and Molecular Imaging, 1999, 26, 1614-1616.	3.3	12
86	Imaging Thromboembolism with Tc-99m–Labeled Thrombospondin Receptor Analogs TP-1201 and TP-1300. Thrombosis Research, 1999, 93, 191-202.	0.8	20
87	Targeting Tumors with Iodine-123 Labeled Deoxyuridine: Distribution and DNA Binding. Cancer Detection and Prevention, 1999, 23, 72-77.	2.1	0
88	99mTc-labeled vasoactive intestinal peptide receptor agonist: functional studies. Journal of Nuclear Medicine, 1999, 40, 352-60.	2.8	44
89	Radiation dosimetry of a 99mTc-labeled IgM murine antibody to CD15 antigens on human granulocytes. Journal of Nuclear Medicine, 1999, 40, 625-30.	2.8	3
90	Effects of a 99mTc-labeled murine immunoglobulin M antibody to CD15 antigens on human granulocyte membranes in healthy volunteers. Journal of Nuclear Medicine, 1999, 40, 2107-14.	2.8	8

#	Article	IF	CITATIONS
91	Synthesis, In Vitro Binding, and Tissue Distribution of Radioiodinated 2-[1251]N-(N-Benzylpiperidin-4-yl)-2-lodo Benzamide, 2-[1251]BP: A Potential σ Receptor Marker for Human Prostate Tumors. Nuclear Medicine and Biology, 1998, 25, 189-194.	0.3	34
92	Improved Antibody Targeting with Interferon-??-2b Conjugate. Journal of Immunotherapy, 1997, 20, 194-195.	1.2	2
93	Radiolabeled somatostatin analogs in prostate cancer. Nuclear Medicine and Biology, 1997, 24, 105-113.	0.3	57
94	Augmenting of tumor uptake of anti-melanoma antibody MEM136: Influence of interferon. Nuclear Medicine and Biology, 1996, 23, 873-879.	0.3	7
95	Effect of interferon-α-2b on the enhancement of tumour uptake of 99Tcm-labelled monoclonal antibodies. Nuclear Medicine Communications, 1996, 17, 346-352.	0.5	4
96	Transient neutropenia: neutrophil distribution and replacement. Journal of Nuclear Medicine, 1996, 37, 489-94.	2.8	9
97	Imaging inflammatory diseases with neutrophil-specific technetium-99m-labeled monoclonal antibody anti-SSEA-1. Journal of Nuclear Medicine, 1996, 37, 1789-95.	2.8	30
98	Radiolabelled peptides. Nuclear Medicine Communications, 1995, 16, 724-732.	0.5	41
99	Radionuclides: Applications in Diagnostic and Therapeutic Nuclear Medicine. Radiochimica Acta, 1995, 70-71, 273-288.	0.5	11
100	Radionuclides: Applications in Diagnostic and Therapeutic Nuclear Medicine. Radiochimica Acta, 1995, 70-71, 273-288.	0.5	24
101	Radiolabelled peptides: now and the future. Nuclear Medicine Communications, 1995, 16, 724-32.	0.5	2
102	Influence of Biological Response Modifiers. Journal of Immunotherapy, 1994, 16, 175-180.	1.2	4
103	Imaging rheumatic joint diseases with anti-T lymphocyte antibody OKT-3. Nuclear Medicine Communications, 1994, 15, 824-830???830.	0.5	40
104	Peptides and Proteins in Radiolabeling of Blood Elements. , 1994, , 187-194.		0
105	Rhenium-labeled somatostatin analog RC-160. 1H NMR and computer modeling conformational analysis. Journal of Biological Chemistry, 1994, 269, 12583-8.	1.6	20
106	Technetium-99m-labeled monoclonal antibodies: influence of technetium-99m binding sites. Journal of Nuclear Medicine, 1994, 35, 876-81.	2.8	12
107	Use of ferrum in MRI of lung parenchyma and pulmonary embolism. Magnetic Resonance Imaging, 1993, 11, 499-508.	1.0	4
108	Evaluation of biological response modifiers in the enhancement of tumor uptake of technetium-99m labeled macromolecules. Journal of Immunological Methods, 1992, 152, 209-216.	0.6	13

#	Article	IF	CITATIONS
109	Technetium-99m labeled monoclonal antibodies: Evaluation of reducing agents. International Journal of Radiation Applications and Instrumentation Part B, Nuclear Medicine and Biology, 1991, 18, 227-233.	0.3	19
110	Technetium-99m-labeled monoclonal antibodies for immunoscintigraphy. Journal of Immunological Methods, 1991, 137, 217-224.	0.6	35
111	Technetium-99m-labeled proteins for imaging inflammatory foci. International Journal of Radiation Applications and Instrumentation Part B, Nuclear Medicine and Biology, 1991, 18, 605-612.	0.3	5
112	Human neutrophils. Nuclear Medicine Communications, 1990, 11, 37-44.	0.5	4
113	MR imaging of pulmonary parenchyma and emboli by paramagnetic and superparamagnetic contrast agents. Magnetic Resonance Imaging, 1990, 8, 625-630.	1.0	14
114	Radiolabeled blood cells: Perspectives and directions. International Journal of Radiation Applications and Instrumentation Part B, Nuclear Medicine and Biology, 1990, 17, 41-47.	0.3	1
115	Preparation and evaluation of new bifunctional chelating agents: a preliminary report. International Journal of Radiation Applications and Instrumentation Part B, Nuclear Medicine and Biology, 1990, 17, 181-188.	0.3	Ο
116	Immunoscintigraphic imaging of inflammatory lesions: Preliminary findings and future possibilities. Seminars in Nuclear Medicine, 1990, 20, 92-98.	2.5	12
117	Human neutrophils: evaluation of adherence, chemotaxis and phagocytosis, following interaction with radiolabeled antibodies. Nuclear Medicine Communications, 1990, 11, 37-43.	0.5	1
118	Determination of reduced disulfide groups in monoclonal antibodies. BioTechniques, 1990, 8, 512-6.	0.8	13
119	Radioiodinated rhodamine-123: Preparationand preliminary evaluation as an agent for tumor scintigraphy. International Journal of Radiation Applications and Instrumentation Part B, Nuclear Medicine and Biology, 1988, 15, 517-524.	0.3	1
120	Potential of Radiolabeled Antiplatelet Antibodies in the Detection of Vascular Thrombi. , 1988, , 831-845.		1
121	Monoclonal antibodies as agents for selective radiolabeling of human neutrophils. Journal of Nuclear Medicine, 1988, 29, 1817-25.	2.8	25
122	Ultrastructure of human platelets following indium-111 labeling in plasma. Nuclear Medicine Communications, 1987, 8, 69-78.	0.5	1
123	Platelet Sequestration in Widespread Pulmonary Hemangiolymphangiectasia Demonstration by Indium-111 Labeled Platelets. Clinical Nuclear Medicine, 1987, 12, 215-216.	0.7	1
124	Monoclonal antibodies for specific cell labeling: Considerations, preparations and preliminary evaluation. International Journal of Radiation Applications and Instrumentation Part B, Nuclear Medicine and Biology, 1987, 14, 51-58.	0.3	7
125	Distribution of Iodized Oil within the Liver after Hepatic Arterial Injection. Radiology, 1987, 164, 585-586.	3.6	2
126	Live bacteria labeled with 1111n. European Journal of Nuclear Medicine and Molecular Imaging, 1987, 13, 266.	2.2	3

#	Article	IF	CITATIONS
127	Comparison of leukocytes labeled with indium-111-2-mercaptopyridine-N-oxide and indium-111 oxine for abscess detection. Journal of Nuclear Medicine, 1987, 28, 438-41.	2.8	7
128	A look at radiolabeled blood cells. International Journal of Radiation Applications and Instrumentation Part B, Nuclear Medicine and Biology, 1986, 13, 147-158.	0.3	1
129	Artifactual Focal Lung Activity with Indium-111 Labeled Leukocytes. Clinical Nuclear Medicine, 1986, 11, 840-841.	0.7	2
130	Radiolabeled Blood Cells: Techniques and Applications. CRC Critical Reviews in Clinical Laboratory Sciences, 1986, 24, 95-122.	1.0	10
131	The Influence of Heparin on the In Vivo Distribution of IN-111 Labeled Platelets. Investigative Radiology, 1985, 20, 198-202.	3.5	2
132	Radiopharmaceuticals for spleen and bone marrow studies. Seminars in Nuclear Medicine, 1985, 15, 229-238.	2.5	39
133	Techniques of Cell Labeling: An Overview. , 1985, , 67-87.		1
134	Evaluation of indium-111-2-mercaptopyridine-N-oxide for labeling leukocytes in plasma: a kit preparation. Journal of Nuclear Medicine, 1985, 26, 518-23.	2.8	11
135	Simplified and efficient labeling of human platelets in plasma using indium-111-2-mercaptopyridine-N-oxide: preparation and evaluation. Journal of Nuclear Medicine, 1985, 26, 510-7.	2.8	21
136	Preparation and evaluation of [99mTc]DEPE as a cardiac perfusion agent. The International Journal of Applied Radiation and Isotopes, 1984, 35, 507-515.	0.7	11
137	Neutrophil labeling: Problems and pitfalls. Seminars in Nuclear Medicine, 1984, 14, 107-117.	2.5	34
138	Discordant Gallium???67 and Indium???111 Leukocyte Images in a Suspected Pelvic Abscess. Clinical Nuclear Medicine, 1984, 9, 654.	0.7	0
139	The significance of chromosomal aberrations in indium-111-labeled lymphocytes. Journal of Nuclear Medicine, 1984, 25, 922-7.	2.8	37
140	Preparation, characterization and evaluation of DMPE as a myocardial imaging agent. The International Journal of Applied Radiation and Isotopes, 1983, 34, 617-624.	0.7	4
141	Radioisotopic Labeling of Platelets: A Historical Perspective. Seminars in Thrombosis and Hemostasis, 1983, 9, 79-85.	1.5	14
142	Detection of pulmonary embolism in man with 111In-labeled autologous platelets. American Journal of Roentgenology, 1982, 138, 945-947.	1.0	12
143	1982 GEORGE SIMON MEMORIAL FELLOWSHIP AWARD Experimental Studies with 111Indium-Labeled Platelets in Pulmonary Embolism. Investigative Radiology, 1982, 17, 367-373.	3.5	18
144	RADIOLABELED BLOOD CELLS: AGENTS FOR DIAGNOSTIC AND KINETIC STUDIES. , 1982, , 115-125.		2

#	Article	IF	CITATIONS
145	Effect of antiarrhythmic drugs on In-111-labeled leukocytes: chemotaxis and adherence to nylon wool. Journal of Nuclear Medicine, 1982, 23, 131-5.	2.8	5
146	Imaging the inflammatory response to acute myocardial infarction in man using indium-111-labeled autologous platelets Circulation, 1981, 63, 826-832.	1.6	22
147	Cell labeling: achievements, challenges, and prospects. Journal of Nuclear Medicine, 1981, 22, 1011-4.	2.8	19
148	Indium-111-labeled human platelets: improved method, efficacy, and evaluation. Journal of Nuclear Medicine, 1981, 22, 381-5.	2.8	89
149	New radionuclides in the diagnosis of obscure infections. Connecticut Medicine, 1981, 45, 302-4.	0.2	1
150	Lactoferrin: its role as a Ga-67-binding protein in polymorphonuclear leukocytes. Journal of Nuclear Medicine, 1981, 22, 32-7.	2.8	59
151	Cyclotron isotopes and radiopharmaceuticals—XXX. Aspects of production, elution and automation of 81Rbî—,81Kr generators. The International Journal of Applied Radiation and Isotopes, 1980, 31, 51-59.	0.7	25
152	A simplified method of selective spleen scintigraphy with Tc-99m-labeled erythrocytes: clinical applications. Concise communication. Journal of Nuclear Medicine, 1980, 21, 413-6.	2.8	23
153	Imaging experimental coronary artery thrombosis with indium-111 platelets Circulation, 1979, 60, 767-775.	1.6	52
154	Desferoxamine Mesylate (Desferal): A Contrast-Enhancing Agent for Gallium-67 Imaging. Radiology, 1979, 131, 775-779.	3.6	20
155	A Simple Method of Spleen Imaging with ^{99m} Tc-Labeled Erythrocytes. Radiology, 1979, 132, 215-216.	3.6	20
156	Imaging experimental infective endocarditis with indium-111-labeled blood cellular components Circulation, 1979, 59, 336-343.	1.6	53
157	Imaging experimental myocardial infarction with indium-111-labeled autologous leukocytes: effects of infarct age and residual regional myocardial blood flow Circulation, 1979, 60, 297-305.	1.6	48
158	Indium-111-labeled human polymorphonuclear leukocytes: viability, random migration, chemotaxis, bacterial capacity, and ultrastructure. Journal of Nuclear Medicine, 1979, 20, 741-7.	2.8	69
159	Technetium-99m stannous pyrophosphate imaging of experimental infective endocarditis Circulation, 1978, 58, 111-119.	1.6	38
160	Indium-111-labeled human platelets: uptake and loss of label and in vitro function of labeled platelets. Translational Research, 1978, 92, 829-36.	2.4	20
161	Kinetics of indium-III labelled lymphocytes in normal subjects and patients with Hodgkin's disease BMJ: British Medical Journal, 1977, 2, 797-799.	2.4	83
162	Imaging of the inflammatory response in ischemic canine myocardium with 111indium-labeled leukocytes. American Journal of Cardiology, 1977, 40, 195-199.	0.7	30

#	Article	IF	CITATIONS
163	Gallium-67 and indium-111 radiopharmaceuticals. The International Journal of Applied Radiation and Isotopes, 1977, 28, 183-201.	0.7	73
164	An experimental comparison of radioactive labels with potential application to lymphocyte migration studies in patients. Clinical and Experimental Immunology, 1977, 29, 509-14.	1.1	53
165	Indium-111-labeled leukocytes for the localization of abscesses: preparation, analysis, tissue distribution, and comparison with gallium-67 citrate in dogs. Translational Research, 1977, 89, 217-28.	2.4	131
166	Gallium-68 labeled red cells and platelets: new agents for positron tomography. Journal of Nuclear Medicine, 1977, 18, 558-62.	2.8	45
167	Indium-111-labeled autologous leukocytes in man. Journal of Nuclear Medicine, 1977, 18, 1014-21.	2.8	193
168	Indium-111-labeled cellular blood components: mechanism of labeling and intracellular location in human neutrophils. Journal of Nuclear Medicine, 1977, 18, 1022-6.	2.8	85
169	Preparation and Evaluation of ¹¹¹ In-Labeled Leukocytes as an Abscess Imaging Agent in Dogs. Radiology, 1976, 119, 731-732.	3.6	80
170	INDIUM-111-LABELLED LEUCOCYTES FOR LOCALISATION OF ABSCESSES. Lancet, The, 1976, 308, 1056-1058.	6.3	125
171	Indium-111 labeled platelets: Studies on preparation and evaluation of in vitro and in vivo functions. Thrombosis Research, 1976, 9, 345-357.	0.8	465
172	Evaluation of a method for the preparation of high specific activity radioionated oestradiol. The International Journal of Applied Radiation and Isotopes, 1976, 27, 585-588.	0.7	17
173	Survey of radioactive agents for in vitro labeling of phagocytic leukocytes. I. Soluble agents. Journal of Nuclear Medicine, 1976, 17, 480-7.	2.8	223
174	Survey of radioactive agents for in vitro labeling of phagocytic leukocytes. II. Particles. Journal of Nuclear Medicine, 1976, 17, 488-92.	2.8	61
175	¹¹¹ In-labelled bleomycin; clinical experience as a diagnostic agent in tumours of the thorax and abdomen. British Journal of Radiology, 1975, 48, 279-285.	1.0	17
176	Analytical control of a radiopharmaceutical using a cathode ray polarograph. Journal of Radioanalytical Chemistry, 1975, 24, 89-97.	0.5	1
177	Studies with radioactive iodine labelled oestrogens as prostate scanning agents. The International Journal of Applied Radiation and Isotopes, 1975, 26, 343-346.	0.7	24
178	The preparation of iodine-123 labelled sodium ortho-iodo hippurate and its clearance by the rat kidneys. The International Journal of Applied Radiation and Isotopes, 1975, 26, 319-320.	0.7	30
179	Cyclotron produced lead-203. Postgraduate Medical Journal, 1975, 51, 751-754.	0.9	17
180	The influence of ligand on the tissue distribution of carrier free 111In in the rat. International Journal of Nuclear Medicine and Biology, 1975, 2, 45-48.	0.7	13

#	Article	IF	CITATIONS
181	The preparation of iodine-123 labelled contrast agents. The International Journal of Applied Radiation and Isotopes, 1974, 25, 576-578.	0.7	12
182	Determination of microgram quantities of gadolinium by cathode-ray polarography. Talanta, 1974, 21, 771-775.	2.9	4
183	The preparation of Indium-111 labelled bleomycin for tumour localisation. The International Journal of Applied Radiation and Isotopes, 1973, 24, 357-359.	0.7	29
184	The production of potassium-43 for medical use. The International Journal of Applied Radiation and Isotopes, 1972, 23, 329-330.	0.7	15
185	Cyclotron produced indium-111 for medical use. The International Journal of Applied Radiation and Isotopes, 1972, 23, 139-140.	0.7	26
186	The Production of 117Sb-labelled potassium antimonyl tartrate for medical use. The International Journal of Applied Radiation and Isotopes, 1970, 21, 33-36.	0.7	4
187	Cyclotron production of carrier-free Gallium-67. The International Journal of Applied Radiation and Isotopes, 1970, 21, 630-631.	0.7	26